<- Go Home
Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.
Market Cap
$52.5M
Volume
8.7K
Cash and Equivalents
$1.0K
EBITDA
-$10.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$4.0M
Profit Margin
1742.17%
52 Week High
$13.00
52 Week Low
$0.90
Dividend
N/A
Price / Book Value
-0.11
Price / Earnings
-1.26
Price / Tangible Book Value
-0.11
Enterprise Value
$136.0M
Enterprise Value / EBITDA
-12.56
Operating Income
-$11.0M
Return on Equity
57.24%
Return on Assets
-33.51
Cash and Short Term Investments
$1.0K
Debt
$7.3M
Equity
-$11.9M
Revenue
$230.0K
Unlevered FCF
-$3.9M
Sector
Biotechnology
Category
N/A